A palm based interactive tailored patient assessment, containing a selection of symptoms, problems and concerns, rating of this items from 1–4 and prioritization for support was tested in 145 lymphoma and leukemia patients in a single centre in Norway. The selleck chemical assessment output was immediately
delivered to treating physicians and nurses in the intervention group. The outcomes measured were the Inhibitors,research,lifescience,medical same assessments: Numbers of symptom problems and concerns addressed, change in symptom distress and need for support. In the intervention group there were more symptoms addressed, less symptom distress measured and patient were less in need for symptom management support [48]. A second randomized controlled trial investigated the effect of the ESRA-C (electronic self-report assessment cancer) on in 660 cancer patients at two institutions. The output from the ESRA-C was displayed to the treatment team in the intervention group. The primary outcome was
the likelihood of discussion of symptoms and quality of life issues (SQLIs) between clinicians and Inhibitors,research,lifescience,medical patients and the secondary endpoints the visit duration and the perceived usefulness by clinicians. When the SQLIs were considered as problematic, they were more frequently discussed during the visit in the intervention group; the length of visit time was equal between the two groups. The clinicians perceived the output as useful [20]. Strengths The strength of our approach, is the defined Inhibitors,research,lifescience,medical clinical setting, chemotherapy in palliative intention, where Inhibitors,research,lifescience,medical disease related symptoms, treatment related toxicities and clinical benefit parameters guide treatment. In contrast to the previous studies which aimed at a general improvement of communication our study aims to improve symptom control due to more in depth symptom assessment and adaption of chemotherapy due to Inhibitors,research,lifescience,medical better monitoring of toxicity and clinical benefit parameters. A second strength is the SKI 606 multicenter setting which tests the intervention in a real life environment and differences
between centers can be further studied. The main focus on specific and generic patient reported outcomes (quality of life, and symptoms) reflects patient centered GSK-3 care in the oncological setting. Limitations E-MOSAIC intervention may be effective on several levels (i.e., awareness of patient, awareness of physician, coping, symptom control, communication), this study tests the hypothesis to overall improve the quality of palliative cancer care, rather than focusing on specific outcomes only. Global single-item QoL indicators are similarly efficient as multi-item scales for overall treatment comparisons and changes over time because they reflect the summation of the individual meaning and importance of various factors [38]. The use of a single-item tool to appropriately obtain a measure of overall QoL was reported from a cooperative multicenter study setting [49]. Patient-rated QoL may be influenced by many factors.